HUMALOG MIX 50/50 (insulin lispro) by Eli Lilly and Company. Approved for insulin analog [epc]. First approved in 1999.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
HUMALOG MIX 50/50 is a rapid-acting insulin analog combination (50% lispro, 50% lispro protamine suspension) administered by subcutaneous injection for glycemic control in diabetes. It combines the fast onset of insulin lispro with an intermediate-acting component to provide both prandial and basal coverage in a single formulation.
Product faces moderate competitive pressure (30/100) with LOE approaching; expect contraction in team size and budget reallocation to newer formulations or biosimilar defense strategies.
Insulin Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec
A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus
A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps
Worked on HUMALOG MIX 50/50 at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on HUMALOG MIX 50/50 offers exposure to a foundational insulin product in a shrinking market segment, with roles centered on defensive market strategies and payer relationships rather than innovation. Career trajectory will depend on Eli Lilly's portfolio consolidation and ability to migrate customers to newer GLP-1 or next-generation insulin products.